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Despite the growing knowledge of the pathogenesis of 
asthma,the prevalence (I ,2) and morbidity of this disease 
have increased over the last two decades as demon- 
strated by the rise in associated hospitalizations (2,3). 
Indeed, asthma is now one of the most common chronic 
diseases, especially in children. It is estimated that 4-l 0% 
of the global paediatric population is affected by asthma 
(4), with around 10% of asthmatic children developing 
symptoms before the age of I year, and over 50% by the 
age of 2years. In the USA alone, the condition affects 
14-15 million people (5,6), and people with asthma 
collectively have more than IO0 million days of restricted 
activity and 470 000 hospitalizations annually. In addition, 
more than 5000 people die each year due to asthma (2). 
Asthma is a chronic inflammatory disorder of the 
airways in which many cells and cellular elements play a 
role, in particular mast cells, eosinophils,T lymphocytes, 
macrophages, neutrophils, and epithelial cells. In 
susceptible individualsthe inflammation causes recurrent 
episodes of wheezing, breathlessness, chest tightness, and 
coughing, especially during the night or in the early 
morning. Such episodes are usually associated with 
widespread, but variable, airflow obstruction that is often 
reversible, either spontaneously or with treatment. The 
inflammation also results in an associated increase in the 
existing bronchial hyperresponsiveness to a variety of 
stimuli (4). 
Information on airways pathology in asthma shows 
that large and small airways often contain plugs 
composed of mucus, serum proteins, inflammatory cells, 
and cellular debris. Microscopic analysis reveals the 
presence of eosinophils and mononuclear cell infiltrates, 
as well as vasodilatation and evidence of microvascular 
leakage and epithelial disruption. These features of 
airways wall remodelling further underscore the 
importance of chronic recurrent inflammation in asthma 
and its effects on the airways. Moreover, such morpho- 
logical changes may not be completely reversible. 
Consequently, research is currently focused on deter- 
mining whether these changes can be prevented or 
modified by early diagnosis, avoidance of factors that 
contribute to asthma severity, and pharmacological 
therapy directed at suppressing airways inflammation. 
Although inflammation can be used to describe a 
variety of conditions in various diseases, inflammatory 
response in asthma has special features that include 
eosinophil infiltration, mast cell degranulation, interstitial 
airways wall injury, and lymphocyte activation. 
Furthermore, there is evidence that TH2 lymphocyte 
cytokine is instrumental in initiating and sustaining the 
inflammatory process (7,8). These observations have 
become important in directing the treatment of asthma. 
It is hypothesized that inflammation is an early and 
persistent component of asthma, and consequently 
treatment to suppress inflammation must be long-term. 
The prevention of long-term respiratory complications 
associated with asthma is based on early and adapted 
management of the condition, and preliminary evidence 
suggests that early intervention with anti-inflammatory 
therapy can modify the disease process (9-l I). 
The use of inhaled corticosteroids at an early stage is 
now a well-established approach to anti-inflammatory 
treatment of asthma (I 2) in order to prevent long-term 
irreversible lung function impairment (I 3) and according 
to international guidelines these drugs should be used as 
first-line therapy in all but very mild cases of the 
condition (14). Indeed, inhaled corticosteroids are 
reported to be the most effective medications for the 
long-term treatment of persistent asthma, with their 
anti-inflammatory effects resulting in control of asthma 
symptoms, improvements in pulmonary function, and a 
reduction in exacerbations (4) and the need for 
bronchodilator rescue therapy (I 5). Furthermore, some 
studies have shown that improvements in asthma control 
achieved with high doses of inhaled corticosteroids are 
associated with improvements in airways inflammation 
markers (I 0, I I). Furthermore, the tolerance of inhaled 
corticosteroids was found to be good in asthmatic 
children with a high safety:efficacy ratio. 
Successful management of asthma depends on 
achieving good deposition of inhaled drug in the lungs, 
while minimizing systemic exposure (I 4).This balance is 
dependent on the amount of drug that reaches the 
airways versus the amount absorbed through the 
gastrointestinal tract and the lung (I 6). The delivery of 
inhaled corticosteroids and their subsequent systemic 
bioavailability are influenced by a number of factors such 
as patient and drug characteristics (including particle 
size, and pharmacokinetic and pharmacodynamic 
properties), and effects of the disease on the airways. 
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Above all, the ideal inhalation system should be practical 
and user-friendly, and able to generate particles of a size 
that allow for optimal distribution of drug in the airways, 
thereby minimizing the amount deposited on the 
oropharynx and swallowed (17). The selection of an 
appropriate delivery system, and its correct usage by the 
patient, are therefore critical influences on the outcome 
of aerosol therapy (I 7,I8). 
A number of different delivery systems are currently 
available for the administration of inhaled therapy, such as 
pressurized metered-dose inhalers (pMDls), with or 
without add-on spacers, dry-powder inhalers (DPls), and 
nebulizers. Topical steroid therapy via dry powder or 
metered-dose inhalation has been shown to be effective 
for treating asthma. Furthermore, nebulizers are widely 
used throughout the world in adult and paediatric 
medical practice for the delivery of inhaled drugs for 
both emergency and acute treatment, and are also 
becoming increasingly popular for long-term domiciliary 
treatment of various respiratory diseases, in particular 
asthma and obstructive pulmonary diseases (I 9). 
Nebulization therapy was first introduced during the 
1960s and I97Os, with &-agonist bronchodilators being 
the first class of drugs used in this form, followed by 
corticosteroids and anticholinergics. 
Treatment with nebulization is useful when large doses 
of inhaled drugs are required, or when the patient’s 
cooperation is low, the aim being to deliver a therapeutic 
dose of the drug as an aerosol in the form of respirable 
particles within a fairly short period of time, usually 
5-10 minutes. It is, however, important to note that 
different nebulizer systems may affect the amount of 
drug that is delivered to the lungs (20).The efficiency of 
a nebulizer depends on several factors, including 
compressor potency, medicine cup characteristics, 
physical properties of the drug to be administered, and 
patient characteristics (collaboration, current volume) 
(21-23). Nebulizers are available as ultrasonic or jet 
models. Both are able to efficiently nebulize drugs in 
solution, but only jet nebulizers are able to nebulize 
drugs such as inhaled steroids in suspension or 
hyperviscous solution (24). In fact, jet nebulizers have 
been shown to be more appropriate than ultrasonic 
nebulizers for the delivery of inhaled steroid therapy in 
asthmatics (I 9). Furthermore, nebulized administration 
of topical steroids is not as efficient on a dose-by-dose 
basis as administration using an MDI: it has been 
estimated that less than 5% of a nebulized dose of a drug 
is delivered to the airways. This may be due to the 
continuous delivery of nebulized drug, irrespective of 
whether the patient is in inspiration or expiration, 
compared with other administration methods that only 
deliver the drug when activated by inspiration. 
Nevertheless, nebulization offers a number of advantages 
over other methods of administration of inhaled drugs 
on account of its ease of use and patient acceptability, 
and hence compliance, since it is less dependent on patient 
co-operation and dexterity. 
Despite the fact that the introduction of MDls, with 
the possible addition of a spacer, and also DPls, has 
simplified and reduced times for the administration of 
inhaled drugs, and reduced the use of nebulized therapy, 
nebulization plays an important role in the treatment and 
prophylaxis of asthma in some patients who are unable 
to use pMDls or DPls correctly or adequately. Many 
patients find it difficult to co-ordinate aerosol discharge 
and inhalation (25,26), which may lead to under- 
treatment with anti-inflammatory medications and over- 
treatment with oral corticosteroids and inhaled 
P-agonists (27).As such, the use of nebulized therapy is 
advocated for young children, the elderly, and severe 
asthmatics where there may be problems with hand-to- 
lung co-ordination or the generation of adequate 
inhalatory flow rates, as well as for the administration of 
high-dose inhaled steroids in steroid-dependent 
asthmatic patients who also require cycles of oral 
corticosteroids (28). Using nebulizers for the 
administration of inhaled drugs in these groups of 
patients can overcome co-ordination problems that are 
associated with pressurized aerosols and inspiratory 
difficulties associated with DPls (29,30). Nebulization 
offers the advantage of requiring minimum co-operation 
during acute asthma attacks, especially in young 
dyspnoeic children, and can be useful in certain cases 
when older children who experience respiratory 
difficulties during severe asthma are so severely 
dyspnoeic that they are unable to operate the valves of 
the spacer. Additionally, when used for the 
administration of corticosteroids to severe asthmatic 
adults nebulization has been shown to allow for a 
reduction in the dosage of oral steroids (3 I). 
Beclometasone dipropionate (BDP) is a topical 
glucocorticosteroid with marked anti-inflammatory and 
antiallergic activity on the bronchial mucosa. It has an 
intense and prolonged anti-inflammatory effect against a 
variety of known antigens. 
BDP has been in extensive clinical use as a suspension 
for nebulization for use with mechanically driven 
(airject) or ultrasonic nebulizers since the mid- 1970s for 
the management of asthma and remains the reference 
drug for inhaled anti-inflammatory therapy in asthma. 
Studies conducted thus far on BDP in asthma have 
demonstrated good efficacy with a low dose-related 
systemic bioactivity (32). 
Although a number of investigators have to date 
compared the efficacy of various delivery systems in 
asthma treatment (33,34), and of specific corticosteroids 
administered via a pMDl (35-40), comparative data on 
the efficacy and safety of different corticosteroids given 
via nebulization are at present limited. However, two 
studies have recently compared inhaled corticosteroids 
administered by nebulization [flunisolide versus 
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budesonide (27), and BDP versus budesonide (I 3)] for 
the treatment of asthmatic children and have reported 
equivalent clinical responses and good safety profiles. 
The primary objective of the series of studies 
reported in this supplement was to investigate the 
efficacy and safety profiles of a new formulation of BDP 
suspension for nebulization (developed by Chiesi 
Farmaceutici SpA, Parma, Italy), when used to treat 
paediatric and adult asthma patients, and to demonstrate 
that these effects were comparable with those of BDP 
given via an MDI (BDP MDI) and of nebulized forms of 
other corticosteroids (namely budesonide and 
fluticasone propionate) that are also currently widely 
used in clinical practice for asthma treatment. 
In the clinical studies reported here, the nebulizer used 
was one that has been previously shown in clinical trials 
to efficiently nebulize inhaled steroids, namely Pari Turbo 
Boy@.This nebulizer has demonstrated a mean MMAD 
(mass mean aerodynamic diameter) of 3.3 ~1 for BDP 2.2 
for fluticasone dipropionate and 5.9 for budesonide, with 
89.2%, 99. I % and 96.6% of particles < 5 p respectively. 
With the new formulation for nebulization of BDP 
[Clenil A@, Becloneb@, Beclospin@] studied in this 
supplement and using a Multistage (5 stage) Liquid 
Impinger, the respirable fraction was around 20%. 
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